# The Role of Fluorodeoxyglucose, $^{18}$F-Dihydroxyphenylalanine, $^{18}$F-Choline, and $^{18}$F-Fluoride in Bone Imaging with Emphasis on Prostate and Breast

Werner Langsteger, MD, FACE,* Martin Heinisch, MD,* and
Ignac Fogelman, BSc, MD, FRCP†

Diagnostic imaging has played a major role in the evaluation of patients with bone metastases. The imaging modalities have included bone scintigraphy, computed tomography, magnetic resonance imaging, and most recently PET/CT, which can be performed with different tracers, including fluorodeoxyglucose (FDG), $^{18}$F-fluoride, $^{18}$F-choline (FCH), and $^{18}$F-DOPA (dihydroxyphenylalanine). For most tumors the sensitivity of FDG in detecting bone metastases is similar to bone scintigraphy; additionally it can be used to monitor the response to chemotherapy and hormonal therapy. $^{18}$F-Fluoride may provide a more sensitive "conventional" bone scan and is superior for FDG nonavid tumors, but, nevertheless, FDG in "early disease" often has clear advantages over $^{18}$F-fluoride. Although more data need to be obtained, it appears that FCH is highly efficient in preoperative management regarding N and M staging of prostate cancer once metastatic disease is strongly suspected or documented. For neuroendocrine tumors and in particular in medullary thyroid cancer, DOPA is similar to $^{18}$F-fluoride in providing high quality information regarding the skeleton. Nevertheless, prospective studies with large patient groups will be essential to define the exact diagnostic role of FCH and DOPA PET in different clinical settings.
Semin Nucl Med 36:73-92 © 2006 Elsevier Inc. All rights reserved.

P ositron emission tomography (PET) previously regarded as a research procedure has become one of the most important and innovative clinical applications in oncology. In comparison with the established conventional imaging modalities (CIM) such as computed tomography (CT), ultrasound, and magnetic resonance imaging (MRI), PET has important advantages. Tomographic images with PET have substantially higher resolution and provide three-dimensional anatomical information,[1] which leads to superior sensitivity and specificity compared with conventional planar and single photon emission computed tomography (SPECT) techniques. Even with persisting high costs, PET is almost routinely used in the clinical management of certain cancer patients;[2,3] in addition, PET has become an efficient modality for whole-body scanning in a reasonably short time.

With the increasing availability of new combined inline PET/CT machines, the possibility of obtaining more detailed and precise CT anatomic localization of PET directed metabolic abnormalities of tumor lesions, especially in skeletal diseases, has become a clinical reality. In a recent study PET/CT was able to clearly differentiate malignant from benign lesions, even in those cases in which only a low dose CT was provided for anatomic correlation.[4] With the newest CT scanner development (32 and 64 slices) an increasing number of unexpected and additional tumor lesions will be detected and will be more easily visualized.[5]

From the clinical point of view different radiopharmaceuticals for PET imaging may be more suitable in various cancers. $^{18}$F-Fluorodeoxyglucose (FDG) as an agent to image altered tumor metabolism has been proven to be sensitive, specific, and cost effective.[6] In particular, the routine use of $^{18}$F-fluoride as a nonspecific bone tracer is also accepted.[7] Both have potential roles in the management of patients with bone metastases (BM).

*PET–CT Center Linz, Department of Nuclear Medicine and Endocrinology, St. Vincent's Hospital, Linz, Austria.
†Division of Imaging, King's College, London, UK.
Address reprint requests to Werner Langsteger, MD, PET–CT Center Linz, Department of Nuclear Medicine and Endocrinology, St. Vincent's Hospital, Seilerstaette 4, A-4020, Linz, Austria. E-mail: werner.langsteger@bhs.at

**Figure 1** ^{18}F-Fluoride clearly shows in the coronal, saggital, and axial slices a metastasis in the vertebral body of T11.

[18]F-Choline (methylcholine; FCH) for imaging of prostate cancer and ^{18}F-DOPA (dihydroxyphenylalanine) in the use of neuroendocrine tumors (NET) and medullary thyroid cancer (MTC) patients remain under review.[8]

## Bone Metastases: General Aspects

Bone metastases occur in up to 70% of breast or prostate cancer patients and in about 15 to 30% in other cancer patients (lung, stomach, uterus, bladder, colon, thyroid, kidney, rectum). About 350,000 people in the United States die with BM every year.[9] Patients can have osteolytic, osteoblastic, or mixed lesions containing both elements.

From pathophysiology it is known that in BM, activated osteoclast cells, osteoblast cells, the mineralization process of bone formation, cancer cells, and inflammatory cells coexist. Several factors, including increasing vascularity (in areas of red marrow) as well as tumor cells producing adhesive molecules thus binding them to bone matrix and marrow stromal cells, account for the frequency of BM.[10]

BM not detected in bone scintigraphy (BS) may be explained by the absence of significant reactive changes in patients with slow growing lesions in which reactive bone is not detectable.[11-13] For treatment monitoring BS can be misleading if performed too early,[14,15] due to an intense osteoblastic response following the instigation of successful therapy—the "flare" response.

## Role of Imaging

### Conventional Imaging Modalities

For the characterization of scintigraphic bone lesions, correlation with CT or MRI is the most common approach, visualizing normal and malignant tissues with great detail.[7,16,17] In the day-to-day practice of medicine CT is used to generate images as tomographic slices, with very high sensitivity and specificity.[18-20]

Early stages of disease may not be detected if no associated structural abnormalities are present. Only with disease progression and in the presence of significant structural abnormalities will anatomic imaging techniques be successful. Nevertheless some disorders may never manifest as structural abnormalities throughout the course of certain diseases.[21]

MRI has added a major dimension in the investigation of soft tissue and bone abnormalities, sometimes also associated with multiple organ disorders.[22-25] Today it is accepted as the most accurate and sensitive (97-100%) imaging modality in detecting vertebral metastases,[26,27] distinctly better for imaging the marrow, the spinal cord, and the adjacent soft tissue structure than for examining bone itself.[28] In the spine and pelvis, MRI is more sensitive than planar bone scintigraphy, whereas BS is more sensitive in the skull and ribs.[26,29-31]

Functional MRI is primarily intended for the assessment of physiological phenomena, such as cerebral blood flow and perfusion.[32,33]

**2 min - 180 min pi**     **4 min - 150 min pi**     **8 min – 90 min pi**

**Figure 2** The quality of $^{18}$F-fluoride imaging is independent from the acquisition time per bed position (2 min 180 min pi versus 4 min 150 min pi versus 8 min 90 min pi).

## Planar and SPECT BS: General Aspects

Although BS is the established reference method for the diagnosis of BM, in daily routine practice it is now less often indicated in breast and prostate cancer patients. Only in high risk groups [eg, prostate cancer with prostate specific antigen (PSA) levels > 20 ng/mL] it is still recommended for preoperative staging as well as for follow-up. Additionally, several studies have shown poor correlation of clinical symptoms and BM;[34,35] therefore BS should generally be performed only in patients with typical bone symptoms.

Due to the fact that conventional planar and SPECT images have limited spatial resolution, quantitative measurements with SPECT are inaccurate. There are also some data showing that SPECT compared with planar scintigraphy was not able to diagnose metastases convincingly.[36] On the other hand studies have shown that the sensitivity of BS could be improved by additional SPECT imaging.[27,37,38] SPECT is superior in the detection of lesions in the posterior vertebral region, but less evident in the body of the vertebra;[39] nevertheless, for that issue, definitive clinically relevant data are not yet published.

The most common false positive scintigraphic findings—especially in elderly patients—are due to other benign bone diseases such as degenerative changes, inflammatory processes, trauma, mechanical stress, and Paget's disease.

In most situations experienced readers will be able to provide a clear cut diagnosis but in a minority of cases additional diagnostic procedures—with additional costs and physician/patient stress—will be required.

We predict that conventional planar gamma camera imaging will be used much less frequently by the end of this decade. Even the role of SPECT as a routine, but still powerful molecular imaging technique will also be questionable at that time.

For the detection of osseous abnormalities we expect that in the coming years conventional bone imaging with $^{99m}$technetium ($^{99m}$Tc)-labeled diphosphonates—performed with nontomographic scanning techniques—will be replaced completely with $^{18}$F-fluoride PET.[21]

## Radiopharmaceuticals

### $^{18}$F-Fluorodeoxyglucose

$^{18}$F-Fluorodexoyglucose (FDG) was first introduced in 1976. FDG is transported in cancer cells by GLUT 1 (glucose transporter protein) and is then phosphorylated by hexokinases (HKII) to FDG-6-phosphate, which is retained within the malignant cells.

Because malignant tumors have a higher glycolytic rate than normal tissue,[40] FDG is most effectively trapped by tumors with slow or absent dephosphorylation. Additionally

**Biopsy GIII**
**GSc      7**
**PSA      3.9**

**Figure 3** Dynamic images of FCH showing intense focal uptake of FCH in the left acetabulum (1 min pi) with corresponding findings in CT and MRI.

FDG accumulation is increased by tumor hypoxia through activation of the glycolytic pathway.[6]

The role of FDG in the differential diagnosis of benign versus malignant bone tumors is limited because of the high FDG uptake[41] in some benign lesions (eg, giant cell tumors). FDG seems to be highly effective in identifying BM at an earlier stage, when only the bone marrow is involved and before a more generalized bone reaction is visualized. In osteolytic metastases FDG accumulation is higher[42] due to a higher glycolytic rate, whereas sclerotic metastases—being relatively acellular due to the presence of a smaller amount of viable tumor tissue—have lower FDG uptake.[42,43]

In comparison with conventional bone scintigraphy, FDG-PET has higher sensitivity and resolution. In addition it provides more information regarding soft tissue diseases.[5,42]

## Standard Uptake Value

In the clinical setting of FDG-PET scanning the semiquantitative parameter standard uptake value (SUV) is most widely used.[44-46] This measure represents the tissue activity within a region of interest corrected for the injected activity and for patient weight or lean body mass. A transmission scan is required for measuring the true tissue activity in attenuation corrected images.

Due to the FDG uptake, the SUV in tumor cells in general is higher than in benign lesions. In one reported study in breast cancer the mean SUV in FDG visible sclerotic lesions was lower (0.95) compared with 3.6 in mixed and 6.6 in osteolytic metastases.[42] In primary bone tumors, nevertheless, a statistical difference in SUV was seen in benign (2.18 ± 1.52) and malignant (4.34 ± 3.19) lesions.[41] For treatment planning and prognosis SUV measurement of FDG-PET might be useful, due to the fact that a SUV decrease of 30 to 40% is correlated to a chemotherapy response.[47,48]

Despite the potential clinical usefulness, to our knowledge there are no published data that have used SUV for bone metabolism measurement with $^{18}$F-PET.[49]

## $^{18}$F-Fluoride

$^{18}$F-Fluoride, a nonspecific bone tracer, first described in 1962 as a bone-imaging agent, was used for skeletal imaging almost 40 years ago.[50] Diffusion through capillaries into bone extracellular fluid leads to a slow exchange of fluoride ions with hydroxyapatite crystals forming fluoroapatite. Due to

**Figure 4** Comparison of ^{18}F-fluoride and FCH showing metastatic bone disease in the ramus os ischii and the superior and inferior pubic rami.

the fact that remodeling and bone turnover is greatest at the surface, it is mainly stored there.[51-53] The "first-pass" extraction of the smaller ^{18}F from blood through the capillary membrane into the bone is almost 100%,[54,55] in comparison to only 64% of the larger phosphonate complexes.

It is well known that the regional clearance of ^{18}F fluoride from plasma to bone is about three times higher in metastatic lesions than in adjacent "benign" bone tissue.[56] In patients with breast cancer the regional fluoride clearance can increase up to 5 to 10 times in lytic and sclerotic metastases.[7]

With the introduction of gamma camera imaging ^{18}F-fluoride was replaced by ^{99m}Tc–labeled diphosphonates, such as methylene diphosphonate (MDP), which is the most commonly used bone seeking agent and the now "classical" bone imaging tracer.[57] Both tracers, showing almost identical uptake mechanisms,[58] accumulate in osteoblastic lesions, whereas predominantly lytic lesions may show—due to the absence of a reactive osteoblastic reaction—poor or absent tracer uptake.[57]

Following the introduction and subsequent improvements of PET scanners, high resolution imaging of the skeleton became increasingly interesting and reintroduced the use of ^{18}F-fluoride for clinical and research applications (Fig. 1). When ^{18}F-fluoride scanning with 8 to 12 mCi and an acquisition time of 3 min in each bed position and at 45-min postinjection (pi) is performed, excellent image quality with higher spatial resolution[59] than conventional BS is obtained. It is worth mentioning that the quality of ^{18}F-fluoride imaging is extremely high, independent of the acquisition time per bed position (Fig. 2).

Although only a few studies comparing ^{18}F-fluoride and MDP exist, ^{18}F-fluoride PET seems to be more sensitive than conventional BS for the diagnosis of BM;[16] somewhat surprisingly, additional lesions were identified mostly in the spine.[5] Showing a high contrast between normal and abnormal bone ^{18}F-fluoride has potential advantages in sensitivity and specificity;[60] therefore its use in the evaluation of BM is highly recommended.[7,16,56,59,61,62]

A potential problem is that ^{18}F-fluoride PET is very sensitive, and minimal degenerative changes could give false positive findings. Again, PET/CT will provide additional information and should improve the differential diagnosis of benign versus malignant lesions.[4]

Schirrmeister and coworkers[39] in 1999 were one of the first to describe a greater accuracy in detecting BM in breast cancer patients compared with conventional BS, thus changing patient management in >10% of cases; nevertheless no statistically significant data are available.

Some authors[61] have proposed combining FDG and ^{18}F-fluoride to more fully evaluate the distribution of skeletal and soft tissue metastases. This simultaneous administration (two-in-one PET method) for better anatomic localization of lesions in soft tissue and the skeleton by having bone landmarks available is an approach that has not been accepted in routine clinical practice.[61]

As it has been suggested that ^{18}F-fluoride is more cost effective than MDP,[63] we can expect that ^{18}F-fluoride will replace bone scintigraphy completely within several years.[39]

## ^{18}F-DOPA

Neuroendocrine tumors are able to express cell membrane neuroamine uptake mechanism and specific receptors (eg, somatostatin receptors). Diagnostic assessment of this heterogeneous group of tumors involves blood, urine, and biochemical examination as well as imaging modalities.



**Figure 5** Pathological high FCH uptake in the prostate (left lobe), multiple retroperitoneal, and iliac lymph node metastases.

**Figure 6** FCH: Pathological uptakes in the cervical spine, L2, and sacrum due to bone metastases. FDG: Only moderate uptake in the cervical spine and sacrum, no pathological uptake in L2.

For staging of gastroenteropancreatic tumors, CIM (eg, CT, MRI, ultrasonography, angiography, endoscopy) are used for precise localization.[64-66] For metabolic imaging established nuclear medicine techniques with ^{123}I metaiodobenzylguanidine, somatostatin receptor scintigraphy, vasoactive intestinal peptide receptor scintigraphy, and PET have been shown to be most effective. Other PET tracers, such as ^{11}C-dihydroxyphenylalanine (for carcinoids and endocrine pancreatic tumors), ^{11}C-hydroxyephedrine (for phaeochromocytomas), and ^{11}C-metomidate (for adrenal cortical tumors), have been developed and partly introduced as routine procedures.[67] FDG-PET has also been used for diagnostic purposes, but has not yet demonstrated significant uptake in well-differentiated neuroendocrine tissues.[64,65,68]

Fluorinated dihydroxyphenylalanine (^{18}F-DOPA), first synthesized 1992, is a precursor for the neurotransmitter dopamine and is commonly used in the imaging of Parkinson's disease. NETs are capable of taking up amino acids, converting them by means of decarboxylation into biogenic amines, which will be finally stored in cell vesicles; the physiological distribution of DOPA is mostly seen in the gallbladder, bile, and intestine (duodenum, pancreas). To further improve the method, and in particular to reduce the high renal excretion of the tracer producing streaky artifacts in an area of interest, oral premedication by the decarboxylase inhibitor carbidopa was introduced to block the aromatic amino acid decarboxylase enzyme. This led to a six-fold decreased renal excretion while the tumor uptake increased three-fold, hence improving the visualization of these tumors.[65,69]

Many molecular imaging and therapy modalities for NETs are currently under investigation or being developed; nevertheless, no single imaging technique identifies all the metastatic sites of NETs. The best results may be obtained using a combination of functional imaging tests such as PET and SRS and morphologic imaging with CT or MRI. The usefulness of these modalities, however, has to be evaluated by well-designed and multicenter studies.

## ^{18}F-Choline

Although in prostate cancer several imaging methods are available, no single one is able to reliably demonstrate local recurrences, malignant lymph nodes, and skeletal metastases.[70-73]

Recurrences—revealed by a rise in the PSA—are not uncommon after an initial curative therapeutic approach (radical prostatectomy or radiation);[74,75] the velocity of PSA increase is used to distinguish local recurrence from distant metastases.[76,77] Additionally, PET suggests itself as a promising method to localize biochemical recurrence after prostate cancer.

FDG-PET in prostate cancer[43] should only be used in carefully selected patient groups.[78-82] Due to the mostly low FDG uptake in prostate cancer, other radiopharmaceuticals have been studied: ^{11}C-choline;[83] and ^{18}F-labeled choline derivatives, including ^{18}F-fluoroethycholine[84-86] and ^{18}F-fluoromethylcholine (FCH), which show high physiological choline uptake in the liver, pancreas, bowel, and urinary excretion system.

**Figure 7** 20 min and 120 min pi intense focal uptake in the right superior pubic ramus (tumor diameter 16 mm); SUV increased from 4.6 to 9.1.

Choline is transported into cells, phosphorylated, and thus trapped within the cells and used for synthesis of phospholipids. It has be shown that malignant cells have elevated levels of choline and an upregulation of choline kinase activity.[87]

In prostate cancer Hara and coworkers[83,84] compared ^{11}C-choline with ^{18}F-labeled choline and found, in terms of spatial resolution, FCH has a slightly higher image quality than the ^{11}C-labeled tracer; contrary to ^{11}C-choline, FCH is eliminated via the kidneys. The benefit of ^{18}F tracers is a longer half life, which is crucial if a cyclotron is not present on site.

With FCH PET, performing dynamic acquisition (starting 1 min pi) is helpful[88,89] to differentiate focal ureter activity versus pathological lymph nodes in the pelvis: focal FCH uptake from the very beginning (minutes 1-4) has to be interpreted as malignant (lymph nodes and bone), while that occurring in later frames (minutes 5-8) as tracer in the ureter. FCH in the urinary bladder also appears at approximately 5 to 8 min pi.[88,89]

[18]F-Fluoride PET/CT scanning seems to be extremely promising as a follow-up procedure,[4] but nevertheless is only indicated in patients with elevated PSA and suspicious BM.

New generation CT and MRI scanners can visualize lymph node or BM with better resolution, but it still remains to be proven whether this also leads to better diagnostic accuracy in prostate cancer.

# Clinical Impact of PET in Different Malignant Tumors

## Prostate Cancer

Prostate cancer is the most common malignant tumor in men, accounting for approximately one third of all cancer diagnoses; in the United States, 230,000 new cases were diagnosed in 2004.[90] It has a variable biology, ranging from indolent low grade to spreading aggressiveness and finally a tendency to metastasize, killing the patient by bone or bone marrow involvement.

To date PSA is the most commonly used screening method for diagnosis and follow-up management, followed by ultrasound-guided biopsies. Individually, nomograms, including information from PSA and Gleason scores (GsC) at biopsy and clinical stage (at presentation), are used to obtain an early diagnosis (more than 70% of prostate cancers are diagnosed, when the tumor is still confined to the organ). Nevertheless a precise staging in an individual patient cannot always be obtained.[91-93] Using clinical examination alone, staging of prostate cancer is underestimated in 30 to 60% of patients.[94]

### The Impact of Bone Scintigraphy

In prostate cancer with predominantly osteoblastic lesions[95] BS again is the most commonly used follow-up imaging method. To date urologists recommend the use of BS in preoperative management only in patients with PSA levels > 10 to 20 ng/mL. In large retrospective studies in patients with PSA < 20 ng/mL, BM were detected only in

**Figure 8** BS: Intense uptake T11 (suspicious for compression fracture), with pathological uptake in the lumbar spine (L3) and ribs. ^{18}F-Fluoride: Clearly shows extensive metastases.

less than 1%.[96-99] Only one study was able to show a probability of more than 5% for a positive bone scan before PSA increased to 40 to 45 ng/mL.[97] In patients with rising PSA after radical prostatectomy or radiation therapy BS is requested in almost 70% of cases[100] as a follow-up procedure.

Nevertheless, with our recent experience we believe that these recommendations have to be critically reviewed. In several cases we were able to show[101] with ^{18}F-fluoride PET/CT the presence of BM even in patients with low PSA levels (Figs. 3 and 4). Therefore, in high risk patients (GsC > 7 or PSA doubling time < 3 months) we recommend ^{18}F-fluoride PET/CT and not BS as the primary staging procedure.

## ^{18}F-Choline

For preoperative staging in prostate cancer FCH seems to be a very efficient tool. In Linz, FCH PET/CT has been routinely performed in more than 150 patients.

For preoperative staging FCH PET/CT was performed in a high risk group of 49 patients with the following inclusion criteria: GsC > 7 or PSA > 10 ng/mL or PSA doubling time < 3 months. In 4% (2/49)—due to the FCH findings—it was possible to downstage the patient, as suspicious lesions de-

tected formerly in BS could be clearly excluded with FCH PET/CT. In 12% (6/49) of the patients FCH PET led to upstaging with concommitant changes in the therapeutic management: instead of surgery, radiation therapy or hormone therapy (HT) was performed. Four patients were upstaged due to BM and 2 patients (with PSA levels about 12 ng/mL) were upstaged due to multiple lymph node metastases (Fig. 5).

In a small, biopsy-proven, prostate cancer–positive subgroup of 18/49 patients, BM could be visualized in 22% (4/18); in 2 of these (PSA 4.0 and 23.9 ng/mL, respectively) lymph node metastases were also diagnosed as present at the time of initial diagnosis.[89]

In one case with PSA 14 and GsC 8, multiple BM were diagnosed with FCH PET/CT. This case is worth mentioning, as several of the FCH positive bone lesions were also positive on FDG; but FDG uptake was markedly reduced compared with the choline uptake (Fig. 6). In general, in almost all cases with BM there was an increase in the SUV when comparing early and late (approximately 120 min pi) FCH images (Fig. 7).

For follow-up, FCH PET/CT was mostly performed in cases of elevated PSA levels. DeJong and coworkers[102] raised the question whether the use of FCH PET after initial therapy should be restricted to patients with PSA > 5 ng/mL. We

**Figure 9** Comparison BS versus ^{18}F-fluoride versus FDG in breast cancer (left breast and axillary LN) in a patient with known fibrous dysplasia since childhood.



**Figure 10** BS: Bone metastases (cervical and lumbar spine, pelvis, left femur). FDG: Only faint to moderate uptake in a few bone metastases (left femur, lumbar spine); generally reduced FDG uptake due to HT. ^{18}F-Fluoride: Additional bone metastases (not yet seen on bone scan) in the skull, cervical, and lumbar (L5) spine, left os pubis, sacroiliacal left.

**Figure 11** Bone metastases in the lumbar spine (L3) clearly seen in $^{18}$F-fluoride, with only minimal FDG uptake (axial slices and coronal slices).



**Figure 12** BS: Pathological compression fracture in lower lumbar spine; metastases in the thoracic spine and in some ribs. FDG and $^{18}$F-fluoride: Multiple bone metastases.

therefore initiated—to our knowledge—the first study to localize with FCH PET/CT recurrences in prostate cancer patients with PSA below 5 ng/mL and have shown that, in 8 of 17 patients with PSA < 5 ng/mL, at least one FCH positive focus could be found, finally confirmed by CT, MRI, biopsy/histology, or the disease follow-up.[103] In one patient, a dedifferentiation of the prostate cancer had apparently occurred: FCH PET-CT showed bone and lymph node metastases, although the PSA level (without any therapy) was as low as 0.03 ng/mL.

As with FDG, the choline uptake during HT (eg, antiandrogen therapy) is also reduced in BM. In patients who have already received HT, the magnitude of the PSA level is likely to be suppressed and may not correlate well with tumor size or metabolism. Moreover, although there are reports of choline uptake decreasing after initiating HT,[104] we do not know whether the influence on choline metabolism and on PSA level occurs in parallel. It cannot be ruled out that the FCH PET signal is influenced less strongly than the PSA level.

In an earlier publication Shreve and coworkers[105] clearly showed in 34 patients that FDG-PET—due to the fact that FDG accumulation in osteolytic metastases is higher[42] than in sclerotic metastases—is less suitable for the detection of BM, in untreated but in particular in patients who had previously received treatment. Morris and coworkers[81] showed in 17 patients with progressive metastatic prostate cancer that FDG was able to discriminate active osseous lesions from quiescent lesions.

## Breast Cancer

In breast cancer (BC) the skeleton is the most common site of distant metastases, and the BS is the most sensitive method of detecting and determining the extent of BM. BC patients have predominantly osteolytic lesions, but 15 to 20% have osteoblastic lesions.[106] Parathyroid hormone–related peptides can be produced by breast cancer cells and other solid tumors, thus stimulating the formation of osteoclasts.[107,108]

In BC a higher number of false negative FDG skeletal lesions compared with nonosseous metastases has been noted[109] and another smaller study also showed a relatively low skeletal sensitivity.[110] These poorer results in BC might be due to the different affinities of simultaneously appearing lytic and sclerotic BM in BC. It is worth commenting that patients with predominantly sclerotic lesions have a longer survival than those with lytic metastases.[42]

Lonneux and coworkers[111] showed in 33 patients with normal bone scintigraphy a high incidence of bone marrow infiltration, concluding that FDG is more sensitive than BS (CIM 6 positive, PET 31 positive BM). Ohta and coworkers[112] compared FDG PET and BS in 51 patients, with a sensitivity of 77.7% for both, whereas FDG specificity was much higher (97.6%) than BS (80.9%). Similar results were also shown by Yang and coworkers[113] who described in 48 patients (1 year follow-up period, 127 lesions overall) an almost identical sensitivity of FDG (95.2%) and BS (93.3%), but a much higher accuracy of FDG with 94.5% versus 78.9% in BS. Stafford and coworkers[114] showed in 24 patients a significant



**Figure 13** Only slight FDG uptake in three bone metastases (spine, hip, pelvis), whereas ^{18}F-fluoride clearly showed multiple bone lesions.

association of SUV changes and overall response rate in FDG PET.

[18]F-Fluoride PET seems to have the potential to replace BS in routine studies of metastatic breast cancer staging (Fig. 8). Nevertheless, FDG-PET can often clarify staging in cases of equivocal conventional findings (Fig. 9).

Similar to choline, the FDG uptake under HT (eg, Novaldex) is also reduced in BM (Figs. 10 and 11).

### Comparison FDG and ^{18}F-Fluoride PET/CT

Overall, in Linz we have performed ^{18}F-fluoride PET/CT in more than 100 patients with different malignant tumors or diseases within the last 2 years. In 20 cancer patients (6 breast, 2 MTC, 2 prostate, 2 CUP, 2 anorectal, 2 ovarian, 1 lung, 1 FTC, 1 renal cell, and 1 urinary bladder) both procedures, FDG and ^{18}F-fluoride, were performed, detecting 150 lesions overall (unpublished data).

From these, 72 lesions (group 1) were FDG and ^{18}F-fluoride positive (Fig. 12). Forty-four lesions were FDG positive but ^{18}F-fluoride negative (group 2). Thirty-four lesions were only ^{18}F-fluoride positive (group 3).

In group 2 most lesions were small osteolytic metastases or located in the bone marrow, whereas group 3 consisted of tumors known to have less FDG avidity, eg, MTC, renal cell carcinoma, or thyroid cancer (Fig. 13).

## Lung

In lung cancer BM are already present in 20 to 30% at initial diagnosis and in 35 to 66% at autopsy;[115-117] nonsmall cell lung cancer (NSCLC) without distant metastases is potentially curable. In approximately 20 to 25% of all lung cancer

**Figure 14** Comparison of PET/CT and SUV changes (pelvis) from September 2003 until February 2005. September 2003: At initial staging extremly high SUV values (14.7), CT almost normal. December 2003: Peripheral sclerotic bone changes on CT and a marked decrease in SUV (4.8). June 2004 and February 2005: Diffuse but markedly sclerotic increase in the bone metastases on CT, whereas SUV values remained unchanged (9.9-11.5).

cases small cell lung cancer (SCLC) will be seen histologically.

Marom and coworkers[118] showed in 100 patients a sensitivity for FDG of 92 versus 50% for BS, thus concluding that FDG-PET is able to eliminate the need for BS in preoperative tumor staging. Jadvan and coworkers[119] compared FDG and

CT findings and showed a higher sensitivity for FDG (75%) than for CT (50%), with an almost similar specificity of 100% versus 98% for CT.[120,121] In 85 mostly NSCLC patients Gayed and coworkers[122] showed in a retrospective study a higher sensitivity (81%), but lower specificity (78%) for BS than for FDG (sensitivity 73%, specificity 88%). The SUV in BM

**Table 1** Comparison of Metabolic Diameter (mDM) and SUV Over Nearly 2 Years Clearly Showing the Changes in Different Sites of Metastases

| Metastases | DOPA 04/03 | | DOPA 09/03 | | DOPA 12/03 | | DOPA 06/04 | | DOPA 02/05 | |
|---|---|---|---|---|---|---|---|---|---|---|
| | mDM | SUV | mDM | SUV | mDM | SUV | mDM | SUV | mDM | SUV |
| C4 | 10 | 5.0 | 15 | 6.8 | 17 | 9.2 | 17 | 8.5 | 12 | 8.0 (RT) |
| L2 | 10 | 2.8 | 10 | 2.6 | 13 | 7.8 | 13 | 3.8 | 18 | 3.9 |
| Sacrum right | – | – | 16 | 7.9 | 21 | 16.1 | 21 | 3.3 | 30 | 15.1 |
| Spina post left | 15 | 8.2 | 25 | 14.7 | 25 | 4.8 | 25 | 11.5 | 30 | 9.9 |
| Sternum | – | – | – | – | 10 | 3.3 | 10 | 5.1 | 15 | 10.2 |
| T12/L1 | – | – | – | – | – | – | – | – | 11 | 8.8 |

**Table 2** Comparison of mDM and SUV in Fluoride, FDG, and DOPA PET/CT

| Metastases 01/2005 | Fluoride | | FDG | | DOPA | |
|---|---|---|---|---|---|---|
| | mDM | SUV | mDM | SUV | mDM | SUV |
| C4 | 17 | 29.5 | – | – | 12 | 8.0 |
| L2 | 28 | 33.5 | 10 | 3.0 | 18 | 3.9 |
| Sacrum right | 35 | 46.5 | 29 | 5.5 | 30 | 15.1 |
| Spina post left | 40 | 61.9 | 31 | 5.6 | 30 | 9.9 |
| Sternum | 10 | 11.4 | – | – | 15 | 10.2 |
| T12/L1 | – | – | – | – | 11 | 8.8 |

ranged between 1.7 and 14.4 and in false positive lesions between 1.4 to 8.9. The authors concluded that there was significantly higher specificity and negative predictive value for FDG, but no significantly higher sensitivity and positive predictive value for BS.

Similar results were shown by Al Sugair and Coleman[123] in 315 lung patients with a higher sensitivity (84%) and lower specificity (84%) for BS and lower sensitivity (67%) but higher specificity (96%) for FDG-PET. Garcia and coworkers[124] compared lung and prostate cancer, detecting more sclerotic metastases on BS than in FDG (especially prostate cancer), whereas in lung cancer patients PET was superior to BS in lytic metastases.

In a prospective study Schirrmeister and coworkers[39] compared in 53 lung cancer patients the diagnostic accuracy of ^{18}F-fluoride with BS and BS + SPECT at initial staging; in this study 12 patients with SCLC and 41 patients with NSCLC were included. The overall frequency of BM was 23% (12/53).

SPECT increased the sensitivity of BS significantly;[39] compared with ^{18}F-fluoride BS underestimated the extent of BM in 58% (7/12). The clinical management changed in 50% (6/12 patients), which was 11% of all cases.

## Differentiated Thyroid Cancer

In differentiated thyroid cancer about 7% of PTC and 34% of FTC patients already have distant metastases at initial diagnosis; of these 27% in PTC and 59% in FTC are located in the bone.[125]

Schirrmeister and coworkers[126] compared BS, ^{18}F-fluoride, and ^{131}I whole body scans in 35 patients (9 PTC, 26 FTC) showing 83% accuracy for BS alone (64-85% sensitivity, 95-81% specificity), whereas the combination of BS and



February 3, 2005  January 27, 2005  January 26, 2005

**Figure 15** Comparison DOPA versus FDG versus ^{18}F-fluoride PET/CT: C4 metastasis (FDG negative, DOPA, and ^{18}F-fluoride positive).

**FDG**

**SUV 5.5**

**DOPA**

**SUV 15.1**

**SACRUM**

**mDM 30 mm**

**F 18**

**SUV 46.2**

**Figure 16** Bone metastases in the sacrum (30 mm diameter): Intense uptake in DOPA (SUV 15.1) and ^{18}F-fluoride (SUV 46.2), only faint FDG uptake (SUV 5.5).

[131]I whole body scans had 97% accuracy (100% sensitivity, 95% specificity). Of the BM, 41 were osteolytic, only 2 mixed; 41% of all metastases were located in the vertebral column, 44% in flat bones (pelvis, scull, sternum, ribs). Nevertheless no data were provided in that study about the detection rate of ^{18}F-fluoride.

## MTC

Based on reports in the recent literature DOPA seems also to be useful as a new functional imaging procedure (injected dose 0.08-0.10 mCi/kg) for MTC as well as for NETs, providing better results than SRS and FDG-PET.[8] The authors showed in MTC patients a low sensitivity for FDG (44%), SRS (52%), and DOPA (63%) compared with a sensitivity of CIM with 81%; however all three methods had a very high specificity of more than 90% compared with 67% for CIM.

We have some initial experience with a modified acquisition protocol starting with a dynamic acquisiton at 1 min after DOPA injection and have been able to clearly show that the DOPA uptake in BM could be visualized—similar to choline—within the very first minutes.

During a follow-up period of more than 18 months, the metabolic diameter (mDM) as well as SUV values of the dif-

ferent bone lesions changed markedly, due to morphological changes that could also be seen on the CT (Fig. 14).

Initially tumor metabolism is increasing or relatively high, then, due to peripheral sclerotic changes in the bone structure, SUV and DOPA metabolism decrease markedly. Later, SUV and in particular also mDM increase again, due to diffuse sclerosis of the BM (Table 1). In several lesions, we could observe an increase of greater than 50%; in these lesions morphological changes detected with CT were seen usually some months later. This phenomenon—similar to FDG[42]—could be explained by DOPA accumulation in osteolytic metastases (located in the bone marrow) being visualized earlier than bone structure changes.

We performed FDG and DOPA PET/CT in 11 MTC patients for primary staging and follow-up in cases of suspected recurrence due to elevated calcitonin or CEA levels. With DOPA we could detect 18 lesions, whereas FDG was only able to show 7 pathological lesions. Furthermore, the DOPA uptake was much higher than with FDG[127,128] as shown in Table 2.

In one case, when comparing ^{18}F-fluoride, FDG, and DOPA, we could clearly see in two BM (C4 cervical spine and sacrum) similar tracer uptake and SUV values for DOPA and ^{18}F-fluoride[127,128] whereas FDG showed reduced metabolic activity (Figs. 15 and 16).

**Figure 17** BS: Only one lesion in the 9th right rib; x-ray negative. $^{18}$F-Fluoride: Multiple bone metastases (spine, ribs, pelvis, femur). FCH: Similar pattern of choline uptake in bone metastases compared with F18 fluoride, slightly reduced uptake due to HT. FDG: intense uptake in multiple bone metastases; additionally multiple liver and lymph node metastases (mediastinum, retroperitonal).



**Figure 18** FDG: No uptake in the thoracic spine (T9), but pathological CT. $^{18}$F-Fluoride: In the preoperative and follow-up images (after 3 months) increased but similar $^{18}$F-fluoride uptake due to bone metastases.

**Figure 19** FDG: Pathological uptakes in the lumbar spine (L2). ^{18}F-Fluoride: In the preoperative staging no pathological ^{18}F-fluoride findings, in the follow-up (3 months later) intense fluoride uptake combined with sclerotic changes on CT.

## Lymphoma

In multiple myeloma, where skeletal metastases are often predominantly marrow based, FDG is more sensitive than conventional BS;[129] clinically in about half of the myeloma cases bone scans are normal despite severe osteolytic bone destruction.[130]

## Osteosarcoma

In osteosarcoma patients the role of FDG remains unclear.[131,132]

## Multitracer Imaging

In rare tumors, eg, NETs, MTC, or highly aggressive breast or prostate tumors, FDG-PET, while very attractive and promising, is not the only imaging "game in town." Other radio-pharmaceuticals, such as fluoride, choline, and DOPA, are very potent procedures providing additional diagnostic information.

In several cases, multitracer imaging will provide insight into the variations of intra- as well as interindividual tumor metabolism (Fig. 15), improving our knowledge about complex tumor metabolism and special pathophysiological mechanisms (Fig. 17).

Not always knowing the ideal "time curve " as to when to perform diagnostic staging and follow-up procedures, early repetition of a diagnostic procedure—due to excessive and

rapid changes in tumor metabolism—may be useful, as shown in Figs. 18 and 19.

A remarkable case of a colorectal cancer could be demonstrated by us showing multiple BM visualized by preoperative FDG staging. At that time ^{18}F-fluoride only visualized two BM in the thoracic spine (T9 and T10). Three months later ^{18}F-fluoride PET/CT also showed a similar pattern to FDG with multiple BM (Fig. 20). To conclude, FDG in "early disease" has clear advantages over ^{18}F-fluoride.

We are tempted to conclude that morphology of metastases (sclerotic, lytic, mixed) is as important as precise localization. Small lesions in long bones show very often an intense osteoblastic response and can therefore easily be diagnosed with ^{18}F-fluoride or BS. On the other hand lesions in the spine may show minimal osteoblastic response and may therefore more easily be diagnosed with FDG.

From the clinical point of view different tracers targeted appropriately should be used for diagnosis and staging of different tumor entities. In breast and lung cancer sensitivity of FDG in detecting BM is similar to BS, although FDG uptake in general is reduced under treatment modalities.

[18]F-Fluoride seems to better visualize BM in FDG negative tumors (renal cell, thyroid) and in FDG avid tumors under therapy (eg, HT in breast cancer patients). The question "do FDG negative and ^{18}F-fluoride, BS or CT positive metastases have any clinical relevance" still remains—an issue that should challenge further studies.

**Figure 20** FDG preoperative staging (February 2005): Multiple metastases in the liver and in the bone (ribs, pelvis, femur, thoracic, and lumbar spine). $^{18}$F-Fluoride preoperative staging (February 2005): Only two bone metastases in the thoracic spine (T9, T10), no more additional bone lesions. $^{18}$F-Fluoride follow-up (May 2005): After 3 months multiple bone metastases.

In MTC patients DOPA is providing more and earlier information than FDG for preoperative staging as well as for follow-up; thus changes in tumor metabolism and SUV may often be seen earlier then with $^{18}$F-fluoride or FDG. In lymphoma and myeloma FDG seems to perform clearly better than bone scintigraphy.

In prostate cancer FDG is less sensitive, but FCH seems to be the tracer of choice for preoperative staging. Dynamic imaging with FCH is almost always valuable in the differential diagnosis between lymph node metastases versus ureter. In most of the cases false positive findings regarding locoregional lymph nodes or bone lesions could be excluded. Nevertheless it is clear that this method is not able to detect micrometastases.

In several cases multitracer imaging or short-term follow-up PET/CT procedures are of great clinical benefit. The value of other PET tracers in BM is still under investigation. Nevertheless, evaluation of cost effectiveness and short- and long-term benefits of PET/CT in clinical decision making and multitracer management has yet to be performed.

## References

1. Cook GJR, Fogelman I: The role of positron emission tomography in the management of bone metastases. Cancer Suppl 88:2927-2933, 2000
2. Valk PE, Pounds TR, Tesar RD, et al: Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol 23:737-743, 1996
3. Gambhir SS, Shepherd JE, Shah BD, et al: Analytical decision model for the cost-effective management of solitary pulmonary nodules. J Clin Oncol 16:2113-2122, 1998
4. Even-Sapir E, Metser U, Flusser G, et al: Assessment of malignant skeletal disease: Initial experience with 18 F–fluoride PET/CT and Comparison between $^{18}$F–fluoride PET and $^{18}$F–fluoride PET/CT. J Nucl Med 45:272-278, 2004
5. Fogelman I, Cook G, Israel O, et al: Positron emission tomography and bone metastases. Semin Nucl Med 35:135-142, 2005
6. Minn H, Clavo AC, Wahl RL: Influence of hypoxia on tracer accumulation in squamous cell carcinoma: In vitro evaluation for PET imaging. Nucl Med Biol 23:941-946, 1996
7. Petren-Mallmin M, Andreasson I, Ljunggren O, et al: Skeletal metastases from breast cancer: Uptake of $^{18}$F-fluoride measured with positron emission tomography in correlation with CT. Skel Radiol 27:72-76, 1998
8. Hoegerle S, Altehoefer C, Ghanem N, et al: $^{18}$F–DOPA positron emission tomography for tumor detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 28:64-71, 2001
9. Mundy GR: Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584-593, 2002
10. Kahn D, Weiner GJ, Ben-Haim S, et al: Positron emission tomographic measurement of bone marrow blood flow to the pelvis and lumbar vertebrae in young normal adults. Blood 83:958-963, 1994
11. Jacobson AF: Bone scanning in metastatic disease, in Collier BD Jr, Fogelman I, Rosenthall L (eds): Skeletal Nuclear Medicine. St Louis, Mosby, 1996, pp 87-123
12. O'Mara R: Skeletal scanning in neoplastic disease. Cancer 37:480-486, 1976
13. Horiuchi-Suzuki K, Saji H, Ohta H: What is the source of the skeletal affinity of $^{99m}$TC-V-DMSA? Eur J Nucl Med Mol Imaging 31:1675-1676, 2004
14. Cook GJ, Fogelman I: The role of nuclear medicine in monitoring treatment in skeletal malignancy. Semin Nucl Med 31:206-211, 2001
15. Koizumi M, Matsumoto S, Takahashi S, et al: Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer. Clin Nucl Med 24:15-20, 1999
16. Schirrmeister H, Guhlmann A, Elsner K, et al: Sensitivity in detecting osseous lesions depends on anatomic localization: Planar bone scintigraphy versus $^{18}$F PET. J Nucl Med 40:1623-1629

17. Bury T, Barreto A, Daenen F, et al: Flourine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 25:1244-1247, 1998

18. Schaner EG, Chang AE, Doppman JL, et al: Comparison of computed and conventional whole lung tomography in detecting pulmonary nodules: A prospective radiologic–pathologic study. Am J Roentgenol 131:51-54, 1978

19. Vanel D, Henry-Amar M, Lumbroso J, et al: Pulmonary evaluation of patients with osteosarcoma: Roles of standard radiography, tomography, CT, scintigraphy, and tomoscintigraphy. Am J Roentgenol 143:519-523, 1984

20. Muhm JR, Brown LR, Crowe JK, et al: Comparison of whole lung tomography and computed tomography for detecting pulmonary nodules. Am J Roentgenol 131:981-984, 1978

21. Alavi A, Kung JW, Zhuang H: Implications of PET based molecular imaging on the current and future practice of medicine. Semin Nucl Med 34:56-69, 2004

22. Crim JR, Cracchiolo A, Bassett LW, et al: Magnetic resonance imaging of the hindfoot. Foot Ankle 10:1-7, 1989

23. Hilpert PL, Friedman AC, Radecki PD, et al: MRI of hemorrhagic renal cysts in polycystic kidney disease. Am J Roentgenol 146:1167-1172, 1986

24. Semelka RC, Bagley AS, Brown ED, et al: Solitary hepatic metastasis: Comparison of dynamic contrast-enhanced CT and MR imaging with fat-suppressed T2-weighted, breathhold T1-weighted FLASH, and dynamic gadolinium-enhanced FLASH sequences. J Magn Reson Imaging 4:319-323, 1994

25. Stark DD, Wittenberg J, Butch RJ, et al: Hepatic metastases: Randomized, controlled comparison of detection with MR imaging and CT. Radiology 165:399-406, 1987

26. Haubold-Reuter BG, Duewell S, Schilcher BR, et al: The value of bone scintigraphy, bone marrow scintigraphy and fast spin-echo magnetic resonance imaging in staging of patients with malignant solid tumors: A prospective study. Eur J Nucl Med 20:1063-1069, 1993

27. Kosuda S, Tatsumi K, Hisaaki Y, et al: Does bone SPECT actually have lower sensitivity for detecting vertebral metastasis than MRI. J Nucl Med 37:975-978, 1996

28. Athanasoulis T, Koutsikos J, Zerva C: What is the source of the skeletal affinity of 99mTC-V-DMSA? Eur J Nucl Med Mol Imaging 31:1673-1674, 2004

29. Smoker WRK, Goderski JC, Knutzon RK, et al: The role of MR imaging in evaluating metastatic spinal disease. Am J Roentgenol 149:1241-1248, 1987

30. Frank JA, Ling A, Patronas NJ, et al: Detection of malignant bone tumors: MR imaging vs scintigraphy. Am J Roentgenol 55:1043-1048, 1990

31. Steinborn MM, Heuck AF, Tiling R, et al: Wholebody bone marrow MRI in patients with metastatic disease to the skeletal system. J Comput Assist Tomogr 23:123-129, 1999

32. Calautti C, Baron JC: Functional neuroimaging studies of motor recovery after stroke in adults: A review. Stroke 34:1553-1566, 2003

33. Grenier N, Basseau F, Ries M, et al: Functional MRI of the kidney. Abdom Imaging 28:164-175, 2003

34. Hetzel M, Hetzel J, Arslandemir C, et al: Reliability of symptoms to determine use of bone scans to identify bone metastases in lung cancer: Prospective study. Br Med J 328:1051-1052, 2004

35. Schirrmeister H, Arslandemir C, Glattnig G, et al: Omission of bone scanning according to staging guidelines leads to futile therapy in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 31:964-968, 2004

36. Savelli G, Maffioli L, Maccauro M, et al: Bone scintigraphy and added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med 45:27-37, 2001

37. Roland J, van den Weygaert D, Krug B, et al: Metastases seen on SPECT imaging despite a normal planar bone scan. Clin Nucl Med 20:1052-1054, 1995

38. Sedonja I, Budihna NV: The benefit of SPECT when added to planar scintigraphy in patients with bone metastases in the spine. Clin Nucl Med 24:407-413, 1999

39. Schirrmeister H, Glattnig G, Hetzel J, et al: Prospective evaluation of the clinical value of planar bone scans, SPECT, and 18F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 42:1800-1804, 2001

40. Warburg O: On the origin of cancer cells. Science 123:306-314, 1954

41. Aoki J, Watanabe H, Shinozaki T, et al: FDG PET of primary benign and malignant bone tumors: Standardized uptake value in 52 lesions. Radiology 219:774-777, 2001

42. Cook GJ, Houston S, Rubens R, et al: Detection of bone metastases in breast cancer by 18FDG PET: Differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 16:3375-3379, 1998

43. Galasko CSB: Skeletal Metastases. London, Butterworths, 1986

44. Paquet N, Albert A, Foidart J, et al: Within-patient variability of 18F-FDG: Standardized uptake values in normal tissues. J Nucl Med 45:784-788, 2004

45. Keyes JW Jr: SUV: Standard uptake or silly useless value? J Nucl Med 36:1836-1839, 1995

46. Ramos CD, Erdi YE, Gonen M, et al: 18F-FDG PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. Eur J Nucl Med 28:155-164, 2001

47. Schulte M, Brecht-Krauss D, Werner M, et al: Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med 40:1637-1643, 1999

48. Franzius C, Bielack S, Flege S, et al: Prognostic significance of (18)F-FDG and (99m) Tc methylene diphosphonate uptake in primary osteosarcoma. J Nucl Med 43:1012-1017, 2002

49. Brenner W, Vernon C, Muzi M, et al: Comparison of different quantitative approaches to 18F-fluoride PET scans. J Nucl Med 45:1493-1500, 2004

50. Blau M, Nagler W, Bender MA: Fluorine-18: A new isotope for bone scanning. J Nucl Med 3:332-334, 1962

51. Blau M, Ganatra R, Bender MA: 18F-Fluoride for bone imaging. Semin Nucl Med 2:31-37, 1972

52. Narita N, Kato K, Nakagaki H, et al: Distribution of fluoride concentration in the rat's bone. Calcif Tissue Int 46:200-204, 1990

53. Ishiguro K, Nakagaki H, Tsuboi S, et al: Distribution of fluoride in cortical bone of human rib. Calcif Tissue Int 52:278-282, 1993

54. Wootton R, Dore C: The single-passage extraction of 18F in rabbit bone. Clin Physiol Meas 7:333-343, 1986

55. Schirrmeister H, Rentschler M, Kotzerke, et al: Darstellung des normalen Skelettsystems mit 18F Na-PET im Vergleich zur konventionellen Skelettszintigraphie mit 99mTc-MDP. Fortschr Röntgenstr 168,5:451-456, 1998

56. Hawkins RA, Choi Y, Huang SC, et al: Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med 33:633-642, 1992

57. Wolfenden JM, Pitt MJ, Durie BGW, et al: Comparison of bone scintigraphy and radiology in myeloma. Radiology 134:723-728, 1980

58. Fogelman I: Skeletal uptake of diphosphonate: A review. Eur J Nucl Med 5:473-476, 1980

59. Hoh CK, Hawkins RA, Dahlbom M, et al: Whole body skeletal imaging with (18F) fluoride ion and PET. J Comput Assist Tomogr 17:34-41, 1993

60. Cook GJR, Fogelman I: The role of positron emission tomography in skeletal disease. Semin Nucl Med 31:50-61, 2001

61. Hoegerle S, Juengling F, Otte A, et al: Combined FDG and (F-18) fluoride whole-body PET: A feasible two-in-one approach to cancer imaging? Radiology 209:253-258, 1998

62. Schirrmeister H, Guhlmann A, Kotzerke J, et al: Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 17:2381-2389

63. Hetzel M, Arslandemir C, Konig HH, et al: F-18 NaF PET for detection of bone metastases in lung cancer: Accuracy, cost-effectiveness, and impact on patient management. J Bone Miner Res 18:2206-2214, 2003

64. Kaltsas G, Rockall A, Papagodias D, et al: Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumors. Eur J Endocrinol 151:15-27, 2004

65. Eriksson B, Bergstrom M, Sundin A, et al: The role of PET in localization of neuroendocrine and adrenocortical tumors. Ann NY Acad Sci 970:159-169, 2002

66. Bombardieri E, Seregni E, Vallano C, et al: Positron of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors. J Nucl Med Mol Imag 48:150-163, 2004

67. Eriksson B, Orefors H, Oberg K, et al: Developments in PET for the detection of endocrine tumors. Best Pract Res Clin Endocrinol Metab 19:311-324, 2005

68. Sundin A, Eriksson B, Bergstrom M, et al: PET in the diagnosis of neuroendocrine tumors. Ann N Y Acad Sci 1014:246-257, 2004

69. Li S, Beheshti M: The radionuclide molecular imaging and therapy of neuroendocrine tumors. Curr Cancer Drug Targets 2:139-148, 2005

70. Moul JW: Prostate specific antigen only progression of prostate cancer. J Urol 163:1632-1642, 2000

71. Huch Boni RA, Meyenberger C, Pok Lundquist J, et al: Value of endorectal coil versus body coil MRI for diagnosis of recurrent pelvic malignancies. Abdom Imaging 21:345-352, 1996

72. Leventis AK, Shariat SF, Slawin KM: Local recurrence after radical prostatectomy: Correlation of US features with prostatic fossa biopsy findings. Radiology 219:432-439, 2001

73. Roudier MP, Vesselle H, True LD, et al: Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: The effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis 20:171-180, 2003

74. Roehl KA, Han M, Ramos CG, et al: Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results. J Urol 172:910-914, 2004

75. Kamat AM, Rosser CJ, Levy LB, et al: Rise in serum PSA of 1.5 ng/mL above 24-month nadir after external beam radiotherapy is predictive of biochemical failure. Urology 63:1132-1137, 2004

76. Partin AW, Pearson JD, Landis PK, et al: Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 43:649-659, 1994

77. Okotie OT, Aronson WJ, Wieder JA, et al: Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol 171:2260-2264, 2004

78. Hermann K, Schöder H, Eberhard S, et al: FDG PET for the detection of recurrent/metastatic prostate carcinoma in patients with rising PSA after radical prostatectomy. J Nucl Med 45:359, 2004

79. Fricke E, Machtens S, Hofmann M, et al: Positron emission tomography with (11) C-acetate and (18) F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging 30:607-611, 2003

80. Larson SM, Morris M, Gunther I, et al: Tumor localization of 16 beta-(18)F- fluoro-5$\alpha$-dihydrotestosterone versus (18)F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 45:366-373, 2004

81. Morris MJ, Akhurst T, Osman I, et al: Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 59:913-918, 2002

82. Nunez R, Macapinlac HA, Yeung HW, et al: Combined 18 F-FDG and 11 C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 43:46-55, 2002

83. Hara T, Kosaka N, Shinora N, et al: PET imaging of brain tumor with (methyl-11C) choline. J Nucl Med 38:842-847, 1997

84. Hara T, Yuasa M: Automated synthesis of fluoroine-18 labeled choline analogue: 2-Fluoroethyol-dimethyl-2-oxytheylammonium. J Nucl Med 38:44, 1997

85. DeGrado TR, Coleman RE, Wang S, et al: Synthesis and evaluation of ^{18}F-labeled choline as an oncologic tracer for positron emission tomography: Initial findings in prostate cancer. Cancer Res 61:110-117, 2001

86. DeGrado TR, Baldwin SW, Wang S, et al: Synthesis and evaluation of ^{18}F-labeled choline analogs as oncologic PET tracers. J Nucl Med 42:1805-1814, 2001

87. Macara IG: Elevated phosphocholine concentration in ras-transformed NIH 3T3 cells arises from increased choline kinase activity, not from phosphatidylcholine breakdown. Mol Cell Biol 9:325-328, 1989

88. Heinisch M, Meier S, Salomon U, et al: Initial experience in F18-fluorocholine PET/CT in prostate cancer: Implications for the determination of a PET/CT acquisition protocol. Q J Nucl Med Mol Imaging 48:7, 2004

89. Langsteger W, Heinisch M, Janetschek G, et al: Diagnosis of prostate cancer with FCH positron emission tomography/computed tomography: First results. Mol Imaging Biol 7:113-114, 2005

90. Jemal A, Tiwari RC, Murray T, et al: Cancer statistics, 2004. CA Cancer J Clin 54:8-29, 2004

91. Partin AW, Kattan MW, Subong EN, et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update. JAMA 277:1445-1451, 1997

92. Kattan MW, Wheeler TM, Scardino PT: Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 17:1499-1507, 1999

93. Kattan MW, Eastham JA, Stapleton AM, et al: A preoperative nomogram for disease reccurence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90:766-771, 1998

94. D'Amico AV, Whittington R, Schnall M, et al: The impact of the inclusion of endorectal coil magnetic resonance imaging in a multivariate analysis to predict clinically unsuspected extraprostatic cancer. Cancer 75:2368-2372, 1995

95. Charhon SA, Chapuy MC, Delvin EE, et al: Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia. Cancer 15:918-924, 1983

96. Chybowski FM, Keller JJ, Bergstralh EJ, et al: Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: Prostate specific antigen is superior to all other clinical parameters. J Urol 145:313-318, 1991

97. Lee CT, Oesterling JE: Using prostate-specific antigen to eliminate the staging radionuclide bone scan. Urol Clin North Am 24:389-394, 1997

98. Cher ML, Bianco FJ Jr, Lam JS, et al: Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radial prostatectomy. J Urol 160:1387-1391, 1998

99. Kane CJ, Amling Cl, Johnstone PA, et al: Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 61:607-611, 2003

100. Ornstein DK, Colberg JW, Virgo KS, et al: Evaluation and management of men whose radical prostatectomies failed: Results of international survey. Urology 52:1047-1054, 1998

101. Langsteger W, Heinisch M, Janetschek G, et al: [18]F Choline PET/CT in preoperative staging of prostate cancer. Nuklearmedizin 44:36, 2005

102. de Jong IJ, Pruim J, Elsinga PH, et al: 11C-Choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 44:32-38, 2003

103. Heinisch M, Dirisamer A, Loidl W, et al: PET/CT with F-18-fluorocholine for restaging of prostate cancer patients: Meaningful at PSA < 5 ng/ml? Mol Imaging Biol (in press)

104. Coleman R, DeGrado T, Wang S, et al: Preliminary evaluation of F-18 fluorocholine (FCH) as a PET tumor imaging agent. Clin Positron Imaging 3:147, 2000

105. Shreve PD, Grossman HB, Gross MD, et al: Metastatic prostate cancer: Initial findings of PET with 2-deoxy-2-(F-18) fluoro-D-glucose. Radiology 199:751-756, 1996

106. Coleman RE, Seaman JJ: The role of zoledronic acid in cancer: Clinical studies in the treatment and prevention of bone metastases. Semin Oncol 28:11-16, 2001

107. Guise Ta, Yin JJ, Taylor SD, et al: Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98:1544-1549, 1996

108. Shen X, Falzon M: PTH-related protein modulated PC-3 prostate cancer cell adhesion and integrin subunit profile. Mol Cell Endocrinol 199:165-177, 2003

109. Moon DH, Maddahi J, Silverman DH, et al: Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent of metastatic breast carcinoma. J Nucl Med 39:431-435, 1998

110. Wahl RL, Cody RL, Hutchins GD, et al: Primary and metastatic breast

carcinoma: Initial clinical evaluation with PET with the radiolabeled glucose analogue 2-(F-18)-fluoro-2-deoxy-D-glucose. Radiology 179: 765-770, 1991

111. Lonneux M, Borbath II, Berliere M, et al: The place of whole-body PET FDG for the diagnosis of distant recurrence of breast cancer. Clin Positron Imaging 3:45-49, 2000

112. Ohta M, Tokuda Y, Suzuki Y, et al: Whole body PET for the evaluation of bony metastases in patients with breast cancer: Comparison with 99Tcm-MDP bone scintigraphy. Nucl Med Commun 22:875-879, 2001

113. Yang SN, Liang JA, Lin FJ, et al: Comparing whole body ^{18}F-2-deoxy-glucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol 128:325-328, 2002

114. Stafford SE, Gralow JR, Schubert EK, et al: Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol 9:913-921, 2002

115. Tritz DB, Doll DC, Ringenberg QS, et al: Bone marrow involvement in small cell lung cancer: Clinical significance and correlation with routine laboratory variables. Cancer 63:763-766, 1989

116. Bezwoda WR, Lewis D, Livini N: Bone marrow involvement in anaplastic small cell lung cancer: Diagnosis, hematologic features, and prognostic implications. Cancer 58:1762-1765, 1986

117. Trillet V, Revel D, Combaret V, et al: Bone marrow metastases in small cell lung cancer: Detection with magnetic resonance imaging and monoclonal antibodies. Br J Cancer 60:83-88, 1989

118. Marom EM, McAdams HP, Erasmus JJ, et al: Staging non-small cell lung cancer with whole-body PET. Radiology 212:803-809, 1999

119. Jadvar H, Gamie S, Ramanna L, et al: Musculoskeletal system. Semin Nucl Med 34:254-261, 2004

120. Tse N, Hoh C, Hawkins R, et al: Positron emission tomography diagnosis of pulmonary metastases in osteogenic sarcoma. Am J Clin Oncol 17:22-25, 1994

121. Franzius C, Daldrup-Link HE, Sciuk J, et al: FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: Comparison with spiral CT. Ann Oncol 12:479-586, 2001

122. Gayed I, Vu T, Johnson M, et al: Comparison of bone and 2-deoxy-2-(18F) fluoro-D-glucose positron emission tomography in the evaluation of bony metastases in lung cancer. Mol Imaging Biol 5:26-31, 2003

123. Al-Sugair A, Coleman R: Relative diagnostic efficiency of F-18 FDG PET and bone scintigraphy for detection of osseous metastases in primary or secondary lung cancer. J Nucl Med 40:20, 1999

124. Garcia JR, Simo M, Perez G, et al: 99m Tc-MDP bone scintigraphy and ^{18}F FDG positron emission tomography in lung and prostate cancer patients: Different affinity between lytic and sclerotic bone metastases. Eur J Nucl Med Mol Imaging 30:1714, 2003

125. Lin JD, Huang MJ, Juang JH, et al: Factors related to the survival of papillary and follicular thyroid carcinoma patients with distant metastases. Thyroid 9:1227-1235, 1999

126. Schirrmeister H, Buck A, Guhlmann A, et al: Anatomical distribution and sclerotic activity of bone metastases from thyroid cancer assessed with F-18 Sodium Fluoride positron emission tomography. Thyroid 11:677-683, 2001

127. Langsteger W: 18 F DOPA PET vs 18 FDG PET in the follow up of MTC patients: Comparison and first results. Mol Imaging Biol 6:87, 2004

128. Langsteger W, Meier S, Heinisch M, et al: Comparison and first results of 18 F DOPA versus FDG PET in the follow up of MTC patients. Q J Nucl Med Mol Imaging 48:6, 2004

129. Moog F, Kotzerke J, Reske SN: FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med 40:1407-1413, 1999

130. Leonard RC, Owen JP, Proctor SJ, et al: Multiple myeloma: Radiology or bone scanning? Clin Radiol 32:291-295, 1981

131. Aoki J, Inoue T, Tomiyoshi K, et al: Nuclear imaging of bone tumors: FDG-PET. Semin Musculoskelet Radiol 5:183-187, 2001

132. Brenner W, Bohuslavizki KH, Eary JF: PET imaging of osteosarcoma. J Nucl Med 44:930-942, 2003